MitraScore: What Does the Final Result of Edge-to-Edge Treatment of Mitral Regurgitation Provide?

Edge-to-edge treatment has proven to be a safe and effective technique in follow-up, decreasing mortality and hospitalizations for heart failure when a good result is achieved.

MitraScore: ¿qué nos aporta en el resultado final para el tratamiento borde a borde de la insuficiencia mitral

The MitraScore was developed to assess the outcome at the end of the procedure. In that sense, results <3 represent mild mitral regurgitation, which would be related to lower mortality, although this has not yet been validated.

Researchers conducted a prospective analysis of the MITRA-PRO Registry, including 1491 patients with primary, secondary, or mixed severe mitral regurgitation. Out of all patients who underwent edge-to-edge treatment, 1059 had a MitraScore ≤3 (71%) and 432 ≥4.

The devices used were MITRACLIP XT, NT, NTR, and XTR.

The groups were similar: mean age was 78 years; 43% of subjects were women; EUROScore = 22; 86% of patients had hypertension, 28% had diabetes, 60% had coronary artery disease, 18% had undergone myocardial revascularization surgery (MRS), 7% had undergone transcatheter aortic valve replacement (TAVR), 70% experienced atrial fibrillation, 22% had a permanent pacemaker, 17% had an Automatic Implantable Cardioverter-Defibrillator (AICD), and 12% had received cardiac resynchronization therapy. More than 50% had moderate or severe tricuspid regurgitation and their ejection fraction was 44%.

The cause of mitral regurgitation was secondary in 56% of the patients, degenerative in 28%, and mixed in the rest of the subjects studied.

Read also: Survival in Patients with Tricuspid Regurgitation According to Clinical and Echocardiographic Variables (Clusters).

There were no differences in terms of pharmacological treatment received.

In-hospital mortality (1.6% vs.1.9%) and MACCE were also similar.

At the one-year follow-up, mortality was lower in patients with MitraScore 3 (14.6% vs. 22.1%; hazard ratio [HR]): 1.63; 95% confidence interval [CI]: 1.25-2.13; p < 0.001), and so were the composite of death and rehospitalizations (31.5% vs. 40.8%; HR: 1.73; 95% CI: 1.35-2.21 p<0.0001), and rehospitalizations and need for reintervention.

Conclusion

The presence of intra-procedural residual mitral regurgitation analyzed by MitraScore after edge-to-edge therapy predicts mortality and rehospitalization at one year. Thus, the MitraScore improves the assessment of residual mitral regurgitation during edge-to-edge therapy and may improve patient survival.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Intraprocedural Residual Mitral Regurgitation and Survival After Transcatheter Edge-to-Edge Repair Prospective German Multicenter Registry (MITRA-PRO).

Reference: Peter Boekstegers, et al. J Am Coll Cardiol Intv 2023;16:574–585.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...